Department of Biomedical and Clinical Sciences, Università di Milano, Milano, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy.
Front Immunol. 2024 Sep 18;15:1436581. doi: 10.3389/fimmu.2024.1436581. eCollection 2024.
Patients with Immune-Mediated Inflammatory Diseases (IMIDs) are known to have an elevated risk of developing cancer, but the exact causative factors remain subject to ongoing debate. This narrative review aims to present the available evidence concerning the intricate relationship between these two conditions. Environmental influences and genetic predisposition lead to a dysregulated immune response resulting in chronic inflammation, which is crucial in the pathogenesis of IMIDs and oncogenic processes. Mechanisms such as the inflammatory microenvironment, aberrant intercellular communication due to abnormal cytokine levels, excessive reparative responses, and pathological angiogenesis are involved. The chronic immunosuppression resulting from IMIDs treatments further adds to the complexity of the pathogenic scenario. In conclusion, this review highlights critical gaps in the current literature, suggesting potential avenues for future research. The intricate interplay between IMIDs and cancer necessitates more investigation to deepen our understanding and improve patient management.
患有免疫介导的炎症性疾病(IMIDs)的患者已知存在罹患癌症的风险增加,但确切的致病因素仍在持续争论中。本叙述性综述旨在介绍有关这两种情况之间复杂关系的现有证据。环境影响和遗传易感性导致免疫反应失调,导致慢性炎症,这在 IMIDs 和致癌过程的发病机制中至关重要。涉及的机制包括炎症微环境、由于异常细胞因子水平导致的异常细胞间通讯、过度修复反应和病理性血管生成。IMIDs 治疗引起的慢性免疫抑制进一步增加了发病情况的复杂性。总之,本综述强调了当前文献中的关键差距,为未来的研究提出了潜在的途径。IMIDs 和癌症之间的复杂相互作用需要进一步研究,以加深我们的理解并改善患者管理。